Trading Signals: HALO Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 27, 2023)(Halozyme Therapeutics Inc)
| HALO latest price $57.7000 (2.4%) ($57.7000 - $57.7000) on Wed. Dec. 7, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.31% (three month average) | RSI | 70 | Latest Price | $57.7000(2.4%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | HALO advances 0.2% a day on average for past five trading days. | Weekly Trend | HALO advances 3.7% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support HALO advance at 0% a week (0% probability) IBB(37%) IFRA(33%) IWO(32%) IWM(31%) IWN(29%) | Factors Impacting HALO price | HALO will decline at least -1.155% in a week (0% probabilities). VIXM(-10%) XBI(-7%) VXX(-6%) IGOV(-6%) GLD(-5%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.155% (StdDev 2.31%) | Hourly BBV | 1.1 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $57.3(0.7%) | 10 Day Moving Average | $56.68(1.8%) | 20 Day Moving Average | $54.97(4.97%) | To recent high | -2.7% | To recent low | 49.6% | Market Cap | $7.886b | | | | Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA. |